Powered by

EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV(TM) Nanocells to Treat Glioblastoma Multiforme

Mar 02, 2017 - PR Newswire

 EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV(TM) nanocell platform for targeted cyto-immunotherapy in cancer, announced that U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EGFR-targeted, doxorubicin-loaded EDV nanocells for the treatment of glioblastoma multiforme (GBM).

Jennifer MacDiarmid, Ph.D., joint-CEO and Director of EnGeneIC, commented, "We are pleased that the FDA has granted Orphan Drug Desi...